Zoetis Inc.
Zoetis Inc.
Your view on ZTS
Overview
What the company does, where it operates, and who runs it.
About Zoetis Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Kristin C. Peck
- Headquarters
- 10 Sylvan Way, Parsippany, NJ, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Kristin C. Peck
- Headquarters
- 10 Sylvan Way, Parsippany, NJ, US
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms.
It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock.
In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health.
It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Zoetis Inc. from FRC's valuation model, read against the market price. ZTS last traded at $84.39, 14.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Zoetis Inc.. Starting points for Zoetis Inc.: P/E 14.2, EPS $6.04, beta 0.68 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Zoetis Inc.. Zoetis Inc. paid $2.12 per share over the last year — a 2.5% yield at the current $84.39 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Zoetis Inc.. Trailing twelve-month EPS for Zoetis Inc. stands at $6.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$97.30
average of 10 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy7
- Hold8
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.21 | $1.49 | $6.31 | $6.31 |
| Low estimate | $1.13 | $1.39 | $6.23 | $5.92 |
| High estimate | $1.32 | $1.63 | $6.39 | $6.60 |
| No. of analysts | 10 | 7 | 9 | 10 |
| Year-ago EPS | $1.48 | $1.53 | $6.02 | — |
| Growth | -18.3% | -2.6% | +4.8% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $2.18B | $2.24B | $9.29B | $9.29B |
| Low estimate | $2.13B | $2.18B | $9.23B | $9.06B |
| High estimate | $2.24B | $2.30B | $9.41B | $9.65B |
| No. of analysts | 9 | 6 | 11 | 12 |
| Year-ago revenue | $2.39B | $2.26B | $9.47B | — |
| Growth | -8.8% | -0.8% | -1.9% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Zoetis Inc.. Zoetis Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ELANElanco Animal Health IncorporatedDrug Manufacturers - Specialty & Generic$13.2B
- IDXXIDEXX Laboratories, Inc.Medical - Diagnostics & Research$55.2B
- MRKMerck & Co., Inc.Drug Manufacturers - General$356.1B
- NEOGNeogen CorporationMedical - Devices$2.4B
- PAHCPhibro Animal Health CorporationDrug Manufacturers - Specialty & Generic$1.4B
More Drug Manufacturers - Specialty & Generic companies
- NPPNYNippon Shinyaku Co., Ltd.OTC$2.3B
- NSRSNorth Springs Resources CorpOTC$35,902
- NUGSCannabis Strategic VenturesOTC$187,588
- NXENNexien BioPharma, Inc.OTC$7,077
- OGIOrganigram Global Inc.NASDAQ$102M
- OGI.TOOrganiGram Holdings Inc.TSX$147M
- OILFFNextleaf Solutions Ltd.OTC$6M
- OILS.CNNextleaf Solutions Ltd.CNQ$8M
- OMIDOMID Holdings, Inc.OTC
- OPTHOptimi Health Corp.NASDAQ$13M
- OPTI.CNOptimi Health Corp.CNQ$27M
- ORGOOrganogenesis Holdings Inc.NASDAQ$104M
ETFs holding Zoetis Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.05%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.04%
- VOVanguard Mid-Cap ETF$103.4B in assets0.28%
- IVViShares Core SP 500 ETF$852.9B in assets0.05%
- MOOVanEck Agribusiness ETF$1.1B in assets6.71%
- IHEiShares US Pharmaceuticals ETF$1.7B in assets4.83%
- FTXHFirst Trust Nasdaq Pharmaceuticals ETF$1.2B in assets3.69%
- PPHVanEck Pharmaceutical ETF$1.1B in assets2.69%
Largest holders first, then the funds most concentrated in ZTS.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Zoetis Inc., and how their positions are changing. At a $34.29B market value, institutional positions materially move Zoetis Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Zoetis Inc. executives and directors. Shares of Zoetis Inc. have traded between $117.09 and $181.85 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Zoetis Inc.. Zoetis Inc. is a $34.29B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Zoetis Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Zoetis Inc.. Coverage tracks Zoetis Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Zoetis Inc.